TYMS is the main target of adjuvant chemotherapy drug (5-FU) in CRC, and its high expression is responsible for the long-term resistance to 5-FU treatment in CRC [4, 5, 36]. The gene discussed is TYMS; the disease is colorectal carcinoma.